DIVISION OF CORPORATION FINANCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Mail Stop 4546

October 7, 2016

Nader Pourhassan, Ph.D. President and Chief Executive Officer CytoDyn Inc. 1111 Main Street, Suite 660 Vancouver, Washington 98660

Re: CytoDyn Inc.

Registration Statement on Form S-3

Filed September 29, 2016

File No. 333-213866

Dear Dr. Pourhassan:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jeffrey Gabor at (202) 551-2544 with any questions.

Sincerely,

/s/ Mary Beth Breslin for

Suzanne Hayes Assistant Director Office of Healthcare and Insurance

cc: Steven Skolnick, Esq. Lowenstein Sandler, LLP